Radiance
Register
Register
Register

ExpertiseUpdated on 26 June 2025

Preclinical Immuno-Modulatory Drug Development in Oncology

Marc Creus

CEO at abbmira therapeutics AG

Basel, Switzerland

About

Abbmira has amassed significant pre-clinical data demonstrating that its experimental small molecule compounds enhance anticancer activity in relevant mouse models via macrophage re-programming. Compound42 binds to a defined intracellular target in tumor associated macrophages (TAMs), which activates these native immune cells to generate an anti-tumor microenvironment.

Field

  • CHE - Chemistry
  • LIF - Life Sciences
  • POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
  • DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings

Organisation

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

Basel, Switzerland

Similar opportunities